npj Precis. Onc.
npj Precision Oncology is a premier open access journal dedicated to advancing the rapidly evolving field of precision cancer medicine. Published by Nature Portfolio in partnership with the Journal of the National Cancer Center, the journal serves as a high-impact platform for cutting-edge research that integrates molecular, genetic, and genomic insights into clinical oncology practice. Its scope encompasses the full spectrum of precision oncology, from the identification of novel biomarkers and therapeutic targets to the development of targeted therapies, immunotherapies, and personalized treatment strategies. The journal also covers critical areas such as tumor heterogeneity, liquid biopsies, pharmacogenomics, and clinical trial design for biomarker-driven interventions. The journal publishes a diverse range of article types, including original research articles, reviews, perspectives, and brief communications, all of which undergo rigorous peer review. Its target audience consists of clinical oncologists, translational researchers, cancer biologists, geneticists, bioinformaticians, and pharmaceutical scientists who seek to translate molecular discoveries into tangible clinical benefits. A defining feature of npj Precision Oncology is its fully open access model, ensuring that all published content is freely and permanently available to the global research community, thereby accelerating the dissemination of impactful findings. With an impressive 2026 Impact Factor of 10.092 and a JCR Quartile ranking of Q1, the journal stands among the most influential and highly cited publications in the oncology and precision medicine landscape, reflecting its central role in shaping the future of cancer care.